We show that intensification of treatment with maraviroc in patients chronically infected with HIV-1 receiving successful long-term antiretroviral therapy was not associated with improvements in HIV-related morbidity, HIV reservoir, microbial translocation, immune activation, or immune exhaustion in either gut or peripheral blood. The measurement of reservoir in both gut and blood longitudinally contributes to a paucity of data in the area.
Get full access to this article
View all access options for this article.
References
1.
VolberdingPA, DeeksSG: Antiretroviral therapy and management of HIV infection. Lancet, 2010; 376:49–62.
2.
KaufmannGR, PerrinL, PantaleoG, OpravilM, FurrerH, TelentiA, HirschelB, LedergerberB, VernazzaP, BernasconiE, RickenbachM, EggerM, BattegayM: CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: The swiss HIV cohort study. Arch Intern Med, 2003; 163:2187–2195.
3.
ChunTW, FauciAS: Latent reservoirs of HIV: Obstacles to the eradication of virus. Proc Natl Acad Sci U S A, 1999; 96:10958–10961.
4.
AnanworanichJ, ChomontN, FletcherJL, PinyakornS, SchuetzA, SeretiI, RerknimitrR, DewarR, KroonE, VandergeetenC, TrichavarojR, ChomcheyN, ChalermchaiT, MichaelNL, KimJH, PhanuphakP, PhanuphakN: Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. J Virus Erad, 2015; 1:116–122.
5.
GutiérrezC, DíazL, VallejoA, et al.: Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: Effect on T cells latently infected. PLoS One, 2011; 6:e27864.
6.
FoxJ, TiraboschiJ, HerreraC, ElseL, DickinsonL, BackD, KhooS, BoffittoM: Pharmacokinetic/pharmacodynamic investigation of single dose oral maraviroc in the context of HIV-1 pre exposure prophylaxis (PrEP). J Acquir Immune Defic Syndr, 2016; 73:252–257.
7.
AsmuthDM, GoodrichJ, CooperDA, HaubrichR, RajicicN, HirschelB, et al.: CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr, 2010; 54: 394–397.
8.
CuzinL, TrabelsiS, DelobelP, et al.: ANRS 145 MARIMUNO Study Group. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study. J Acquir Immune Defic Syndr, 2012; 61:557–564.
9.
FunderburgN, KalinowskaM, EasonJ, GoodrichJ, HeeraJ, MayerH, et al.: Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One, 2010; 5:e13188.
10.
HuntPW, ShulmanNS, HayesTL, et al.: The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: A randomized trial. Blood, 2013; 121:4635–4646.
11.
JiangW, LedermanMM, HuntP, SiegSF, HaleyK, RodriguezB, LandayA, MartinJ, SinclairE, AsherAI, DeeksSG, DouekDC, BrenchleyJM: Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis, 2009; 199:1177–1185.
12.
WilliamsJP, HurstJ, StohrW: HIV-1 DNA predicts disease progression and post-treatment virological control. eLife, 2014; 3:e03821.
13.
Bologna-MolinaR, Damián-MatsumuraP, Molina-FrecheroN: An easy cell counting method for immunohistochemistry that does not use an image analysis program. Histopathology, 2011; 59:801–803.
